Emerging evidence
More
AI slide analysis could better predict melanoma risk, but it is not ready for clinics
Study title: Melanoma Prognostication Using AI-Guided Histopathology
- Evidence type
- Commentary, opinion, or narrative review
- Sources
- 1 sourcePeer-reviewed
- Published
- 1 min read
- Truvace record
- TRV-2026-1247cite or check it
Study title: Melanoma Prognostication Using AI-Guided Histopathology
By October 2026, a review in the International Journal of Dermatology examined how computational pathology and convolutional neural networks applied to H&E whole-slide images could improve melanoma diagnosis and risk stratification beyond current AJCC staging, including integration with transcriptomic and spatial proteomic data.
Read the study abstract
Accurate diagnosis and risk stratification are central for optimal management of patients with melanoma. Current American Joint Committee on Cancer (AJCC) staging systems inadequately stratify patients with clinically meaningful metastatic potential. Manual histopathologic interpretation compounds this limitation, particularly for diagnostically ambiguous lesions at the benign-malignant interface, where concordance is highly variable. This review examines how computational pathology and convolutional neural netw…

The gain
Deep learning models applied to H&E whole-slide images can reliably identify melanomas at risk of recurrence and progression, improving diagnosis and personalized risk stratification for stage I-III cutaneous melanoma.
The problem
Dataset diversity, external validation, interpretability, and generalizability limitations across populations and imaging protocols currently prevent clinical adoption of AI histopathology tools for melanoma.
In brief
The work matters because more accurate identification of melanomas at risk of recurrence could enable personalized management for stage I-III disease, but uncertainty remains about whether models will generalize across diverse populations and acquisition protocols and achieve sufficient validation and explainability for clinical adoption.
Main points
- Review examined convolutional neural networks and deep learning applied to hematoxylin and eosin whole-slide images for melanoma diagnosis, subtype classification, and survival prediction.
- Authors propose integrating H&E-based models with transcriptomic and spatial proteomic data to enhance predictions and provide mechanistic explainability.
- Current AJCC staging inadequately stratifies patients with metastatic potential, and manual interpretation shows highly variable concordance for ambiguous lesions at the benign-malignant interface.
The full story
The review surveyed published deep learning models applied to H&E WSIs for melanoma diagnosis, subtype classification, and survival prediction, noting that manual histopathologic interpretation compounds staging limitations especially for diagnostically ambiguous lesions at the benign-malignant interface.
Authors outline a path toward explainable, multimodal prognostic tools that integrate H&E WSIs with spatial molecular profiling, aiming to standardize diagnosis, discover novel prognostic features, and inform individualized treatment strategies for stage I-III CM.
Sources
1 on file- International Journal of Dermatologydoi:10.1111/ijd.70585
ace
What readers say